News archive
Showing 688 results
June 2015
-
Media Release
Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma
- Data show adult patients may achieve durable response rates, with 13 of 19 evaluable patients with relapsed/refractory non-Hodgkin lymphomas responding to therapy(1)- Recent milestones for Novartis… -
Media Release
Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma
May 2015
-
Media Release
Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
-- Final analysis of COMBI-d confirms overall survival benefit of combination therapy in patients with BRAF V600E/K mutation-positive metastatic melanoma-- Tafinlar and Mekinist in combination… -
Media Release
Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
-
Media Release
Novartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies
- EXPEDITION trial results demonstrated QVA149 (indacaterol/glycopyrronium) met all primary and secondary endpoints(1),(2),(3),(4)- Treatment with QVA149 for 12 weeks provided robust dual… -
Media Release
Novartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies
March 2015
-
Media Release
Novartis announces FDA approval for Jadenu™ to simplify treatment administration for patients with chronic iron overload
- Jadenu (deferasirox), a new formulation of Exjade (deferasirox), is the only once-daily oral tablet for iron chelation- Jadenu, taken with or without food, simplifies daily treatment administration… -
Media Release
Novartis announces FDA approval for Jadenu™ to simplify treatment administration for patients with chronic iron overload
-
Media Release
Novartis presents Cosentyx™ two-year efficacy and safety data showing sustainable effect in psoriasis patients
- New data at AAD shows 7 out of 10 psoriasis patients who were PASI 75 responders at 52 weeks achieved clear to almost clear skin (PASI 90) after two years of Cosentyx 300 mg treatment- After two… -
Media Release
Novartis presents Cosentyx™ two-year efficacy and safety data showing sustainable effect in psoriasis patients
-
Media Release
New Novartis data show more Cosentyx™-treated psoriasis patients achieved clear or almost clear skin (PASI 90) compared to Stelara®
- Phase IIIb CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx™ (secukinumab) compared to Stelara® (ustekinumab) at Week 16- In… -
Media Release
New Novartis data show more Cosentyx™-treated psoriasis patients achieved clear or almost clear skin (PASI 90) compared to Stelara®